Molecular epidemiology of Coxsackievirus B3

被引:24
|
作者
Chu, Pei-Yu [2 ]
Ke, Guan-Ming [1 ]
Chen, Yao-Shen [3 ,4 ,5 ]
Lu, Po-Liang [1 ,6 ]
Chen, Hsiu-Lin [7 ,8 ]
Lee, Min-Sheng [9 ]
Chen, Bao-Chen [4 ]
Huang, Tsi-Shu [4 ]
Li, Yu-Chen [2 ]
Chou, Li-Chiu [6 ]
Wang, Sheng-Yu [6 ]
Lin, Kuei-Hsiang [1 ]
机构
[1] Kaohsiung Med Univ, Coll Med, Sch Med, Dept Clin Lab, Kaohsiung 80705, Taiwan
[2] Kaohsiung Med Univ, Coll Hlth Sci, Fac Biomed Lab Sci, Kaohsiung 80705, Taiwan
[3] Kaohsiung Vet Gen Hosp, Div Infect Dis, Kaohsiung, Taiwan
[4] Kaohsiung Vet Gen Hosp, Dept Pathol & Lab Med, Div Microbiol, Kaohsiung, Taiwan
[5] Natl Yang Ming Med Univ, Dept Internal Med, Taipei, Taiwan
[6] Kaohsiung Med Univ Hosp, Dept Lab Med, Kaohsiung, Taiwan
[7] Kaohsiung Med Univ Hosp, Dept Pediat, Kaohsiung, Taiwan
[8] Kaohsiung Med Univ, Coll Med, Fac Med, Dept Resp Therapy, Kaohsiung 80705, Taiwan
[9] Kaohsiung Med Univ Hosp, Dept Pediat, Kaohsiung, Taiwan
关键词
Coxsackievirus B3 (CV-B3); Molecular epidemiology; Taiwan; VIRUS; ENTEROVIRUSES; MYOCARDITIS; PLECONARIL; HEPATITIS; INFECTION; SEQUENCES; SELECTION; TAIWAN; MATRIX;
D O I
10.1016/j.meegid.2010.04.004
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Molecular epidemiological characteristics are needed to understand the impact of Coxsackievirus B3 (CV-B3) infection, since no CV-B3 genotyping literature is available. Twenty-nine CV-B3 Taiwan strains obtained from 1992 to 2005 were analyzed. A phylogenetic tree was constructed based on the 290 nucleotide sequence of the VP1 gene of Taiwan isolates and in 91 other CV-B3 GenBank sequences. Five genotypes (GI-GV) were depicted. The GI, GII, and GIII were dominant in America and Europe, whereas GIV and CV were prevalent in Asia. In Taiwan, a transient outbreak of GIV occurred in 2000, while CV has been the main genotype circulating since 1992. Patient age ranged from 0.1 to 81 months (median, 4.3 months). The male:female ratio was 1.9:1. More than 60% (17/29) of cases involved children younger than 1 year. Half of them contracted respiratory tract infection (12/24). Nine of the 24 (37.5%) cases with available medical records had central nervous system (CNS) involvement. Eight of the nine patients were younger than 3 months. The CV-B3 has evolved and circulated for the past 60 years. Although the nucleotide sequence of the VP1 is highly variably, amino acids were relatively conserved within the same genotype of CV-B3. CNS infections were not associated with a specific strain or genotype. The CV-B3 poses a significant health threat to children younger than 1 year, especially those younger than 3 months old. (C) 2010 Elsevier B.V. All rights reserved.
引用
收藏
页码:777 / 784
页数:8
相关论文
共 50 条
  • [41] Development of troponin autoantibodies in experimental coxsackievirus B3 myocarditis
    Latva-Hirvela, J.
    Kyto, V.
    Saraste, A.
    Eriksson, S.
    Vuorinen, T.
    Pettersson, K.
    Saukko, P.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2009, 39 (06) : 457 - 462
  • [42] Coxsackievirus B3 infection reduces female mouse fertility
    Shim, Hye Min
    Hwang, Ji Young
    Lee, Kyung Min
    Kim, Yunhwa
    Jeong, Daewon
    Roh, Jaesook
    Choi, Hyeonhae
    Hwang, Jung Hye
    Park, Hosun
    EXPERIMENTAL ANIMALS, 2015, 64 (04) : 343 - 352
  • [43] Coxsackievirus B3 targets TFEB to disrupt lysosomal function
    Mohamud, Yasir
    Tang, Hui
    Xue, Yuan Chao
    Liu, Huitao
    Ng, Chen Seng
    Bahreyni, Amirhossein
    Luo, Honglin
    AUTOPHAGY, 2021, 17 (12) : 3924 - 3938
  • [44] Coxsackievirus B3 induction of NFAT: Requirement for myocarditis susceptibility
    Huber, S. A.
    Rincon, M.
    VIROLOGY, 2008, 381 (02) : 155 - 160
  • [45] Prevention of Cardiac Dysfunction in Acute Coxsackievirus B3 Cardiomyopathy by Inducible Expression of a Soluble Coxsackievirus-Adenovirus Receptor
    Pinkert, Sandra
    Westermann, Dirk
    Wang, Xiaomin
    Klingel, Karin
    Doerner, Andrea
    Savvatis, Konstantinos
    Groessl, Tobias
    Krohn, Stefanie
    Tschoepe, Carsten
    Zeichhardt, Heinz
    Kotsch, Katja
    Weitmann, Kerstin
    Hoffmann, Wolfgang
    Schultheiss, Heinz-Peter
    Spiller, O. Brad
    Poller, Wolfgang
    Fechner, Henry
    CIRCULATION, 2009, 120 (23) : 2358 - 2366
  • [46] Miltefosine reduces coxsackievirus B3 lethality of mice with enhanced STAT3 activation
    Zhang, Chun Yu
    Hung, Cheng-Huei
    Hsiao, Yi-Ling
    Chang, Tung-Miao
    Su, Yu-Chieh
    Wang, Li-Chiu
    Wang, Shih-Min
    Chen, Shun-Hua
    ANTIVIRAL RESEARCH, 2024, 223
  • [47] Gene silencing of VP1 gene of coxsackievirus B3 neurotropic strain Nancy by dsRNAs and siRNAs
    Petrov, Nikolay
    Stoyanova, Mariya
    Stoyanova, Adelina
    Nikolova, Ivanka
    Grozdanov, Petar
    Galabov, Angel
    BIOTECHNOLOGY & BIOTECHNOLOGICAL EQUIPMENT, 2022, 36 (01) : 353 - 361
  • [48] Protective Effects of 20(S)-Protopanaxtriol on Viral Myocarditis Infected by Coxsackievirus B3
    Wang, Xiaoyan
    Wang, Yafeng
    Ren, Zhe
    Qian, Chuiwen
    Li, Yicheng
    Wang, Qingduan
    Zhang, Yan
    Zheng, Liyun
    Jiang, Jinhua
    Yang, Chongren
    Wang, Dong
    Zhang, Yingjun
    Fan, Jianglin
    Wang, Yifei
    PATHOBIOLOGY, 2012, 79 (06) : 285 - 289
  • [49] Antiviral activity of Bifidobacterium adolescentis SPM1605 against Coxsackievirus B3
    Kim, Min Ji
    Lee, Do Kyung
    Park, Jae Eun
    Park, Il Ho
    Seo, Jae Gu
    Ha, Nam Joo
    BIOTECHNOLOGY & BIOTECHNOLOGICAL EQUIPMENT, 2014, 28 (04) : 681 - 688
  • [50] Oncolytic activity of a coxsackievirus B3 strain in human endometrial cancer cell lines
    Lin, Yanzhen
    Wang, Wei
    Wan, Junkai
    Yang, Ying
    Fu, Wenkun
    Pan, Dequan
    Cai, Linli
    Cheng, Tong
    Huang, Xiumin
    Wang, Yifeng
    VIROLOGY JOURNAL, 2018, 15